Vivesto

Vivesto AB is a specialty pharmaceutical company focused on developing new therapeutic options for patients with difficult-to-treat cancers. It has an emerging clinical-stage asset pipeline targeting advanced cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a collaboration with Elevar Therapeutics, Inc. The development portfolio includes Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel, in development for advanced prostate cancer. Vivesto possesses proprietary drug delivery technology aimed at enhancing solubility, efficacy, and safety.